Patrick Amstutz
Vermogen: 3 M $ op 30-06-2026
Vermogen: 3 M $ op 30-06-2026
Patrick Amstutz is the founder of Molecular Partners AG, founded in 2004, holding the title of Chief Executive Officer & Director since 2017.
Dr. Amstutz currently holds the positions of Chief Executive Officer & Director at Molecular Partners, Inc. and President at the Swiss Biotech Association since 2022.
Dr. Amstutz completed a doctorate at the University of Zurich and a graduate degree at the Swiss Federal Institute of Technology.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-12-2025 | 759.913 ( 1,88% ) | 3 M $ | 30-06-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| MOLECULAR PARTNERS AG | Oprichter | 22-11-2004 |
Swiss Biotech Association
Swiss Biotech Association Miscellaneous Commercial ServicesCommercial Services Operates as an industry association | President | 03-05-2022 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Algemeen Directeur | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
University of Zurich
University of Zurich Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Swiss Federal Institute of Technology
Swiss Federal Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Molecular Partners AG
Molecular Partners AG BiotechnologyHealth Technology Engages in discovery, development and commercialization of biopharmaceutical products | Health Technology |
Swiss Biotech Association
Swiss Biotech Association Miscellaneous Commercial ServicesCommercial Services Operates as an industry association | Commercial Services |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau